Roche Receives 510(k) Clearance & CLIA Waiver for Cobas Liat Multiplex Assay Panels to Diagnose Sexually Transmitted Infections
Shots:
- The US FDA has granted 510(k) clearance & CLIA waiver for Cobas liat STI multiplex assay panels (CT/NG & CT/NG/MG), commercially available under the CE mark in upcoming months
- The CT/NG (chlamydia & gonorrhea) & CT/NG/MG (chlamydia, gonorrhea & Mycoplasma genitalium) assays compliment the existing portfolio of singleplex & multiplex tests of Cobas liat for a variety of pathogens incl. SARS-CoV-2, influenza A/B, Strep A., & C. diff
- These panels enable easy & rapid diagnoses of multiple STIs with a single sample using gold-standard PCR technology to produce the results within ≤20 min.
Ref: Globenewswire | Image: Roche
Related News:- Roche Reports the P-IIb (PADOVA) Trial Data of Prasinezumab for Early-Stage Parkinson’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
